tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Dumont FJ et al. | Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. | 1990 | J. Immunol. | pmid:1688572 |
| Woo J et al. | Immunosuppressive activity of FK-506 in rats: flow cytometric analysis of lymphocyte populations in blood, spleen and thymus during treatment and following drug withdrawal. | 1990 | Clin. Exp. Immunol. | pmid:1689226 |
| Dumont FJ et al. | The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells. | 1990 | J. Immunol. | pmid:1689353 |
| Brown Z and Neild GH | FK-506 and haemolytic uraemic syndrome. | 1990 | Lancet | pmid:1689442 |
| Thomas J et al. | The immunosuppressive action of FK506. In vitro induction of allogeneic unresponsiveness in human CTL precursors. | 1990 | Transplantation | pmid:1689518 |
| Murase N et al. | Induction of liver, heart, and multivisceral graft acceptance with a short course of FK 506. | 1990 | Transplant. Proc. | pmid:1689906 |
| Hoffman AL et al. | The effect of FK 506 on small intestine allotransplantation in the rat. | 1990 | Transplant. Proc. | pmid:1689907 |
| Lee KK et al. | Successful orthotopic small bowel transplantation with short-term FK 506 immunosuppressive therapy. | 1990 | Transplant. Proc. | pmid:1689908 |
| Ueda Y et al. | Induction of graft acceptance after dog kidney or liver transplantation. | 1990 | Transplant. Proc. | pmid:1689909 |
| Ohara K et al. | Toxicologic evaluation of FK 506. | 1990 | Transplant. Proc. | pmid:1689910 |
| Nalesnik MA et al. | The effect of FK 506 and CyA on the Lewis rat renal ischemia model. | 1990 | Transplant. Proc. | pmid:1689911 |
| Francavilla A et al. | FK 506 as a growth control factor. | 1990 | Transplant. Proc. | pmid:1689912 |
| Mazzaferro V et al. | Studies of the hepatotrophic qualities of FK 506 and CyA. | 1990 | Transplant. Proc. | pmid:1689913 |
| Standaert RF et al. | Molecular cloning and overexpression of the human FK506-binding protein FKBP. | 1990 | Nature | pmid:1696686 |
| Tropschug M et al. | Isolation and sequence of an FK506-binding protein from N. crassa which catalyses protein folding. | 1990 | Nature | pmid:1696687 |
| Randall T | New antirejection drugs anticipated. | 1990 | JAMA | pmid:1696999 |
| Metcalfe S et al. | FK 506 and cyclosporine A: early effects on activation and gene induction in mouse spleen cells. | 1990 | Transplant. Proc. | pmid:1697107 |
| Morris RE et al. | A study of the contrasting effects of cyclosporine, FK 506, and rapamycin on the suppression of allograft rejection. | 1990 | Transplant. Proc. | pmid:1697111 |
| Woo J et al. | Flow cytometric analysis of lymphocyte populations and activation antigen expression in blood and lymphoid tissues of FK 506-treated rats. | 1990 | Transplant. Proc. | pmid:1697112 |
| Woo J et al. | Effects of FK 506 and low concentration cyclosporine on human lymphocyte activation antigen expression: a flow cytometric analysis. | 1990 | Transplant. Proc. | pmid:1697113 |
| Propper DJ et al. | Low-dose FK 506 inhibits sensitisation after blood transfusions. | 1990 | Transplant. Proc. | pmid:1697114 |
| Tiebosch A et al. | Side effects of FK 506 in cynomolgus monkeys: a histopathologic study. | 1990 | Transplant. Proc. | pmid:1697115 |
| Murase N et al. | FK506 suppression of heart and liver allograft rejection. II: The induction of graft acceptance in rats. | 1990 | Transplantation | pmid:1700504 |
| Burke MD et al. | Inhibition of the metabolism of cyclosporine by human liver microsomes by FK506. | 1990 | Transplantation | pmid:1700507 |
| Wicker LS et al. | Suppression of B cell activation by cyclosporin A, FK506 and rapamycin. | 1990 | Eur. J. Immunol. | pmid:1700753 |
| Sigal NH et al. | Observations on the mechanism of action of FK-506. A pharmacologic probe of lymphocyte signal transduction. | 1990 | Biochem. Pharmacol. | pmid:1700909 |
| Hara S et al. | The effects of a new immunosuppressive agent, FK506, on the glomerular injury in rats with accelerated nephrotoxic serum glomerulonephritis. | 1990 | Clin. Immunol. Immunopathol. | pmid:1700936 |
| Murase N et al. | Effect of FK 506 on spontaneous diabetes in BB rats. | 1990 | Diabetes | pmid:1700959 |
| Kawashima H and Mochizuki M | Effects of a new immunosuppressive agent, FK 506, on the efferent limb of the immune responses. | 1990 | Exp. Eye Res. | pmid:1701148 |
| Siekierka JJ et al. | The cytosolic-binding protein for the immunosuppressant FK-506 is both a ubiquitous and highly conserved peptidyl-prolyl cis-trans isomerase. | 1990 | J. Biol. Chem. | pmid:1701173 |
| Wasik M et al. | Effect of FK-506 and cyclosporine on human T and B lymphoproliferative responses. | 1990 Jul-Aug | Immunopharmacology | pmid:1699911 |
| MacLeod AM and Thomson AW | [FK-506. A new immunosuppressive drug]. | 1990 Jul-Sep | Medicina (Firenze) | pmid:1706817 |
| Naouri A and Tissot E | [Indications for liver transplantation in adults]. | 1990 Jun-Jul | J Chir (Paris) | pmid:1698800 |
| Gailliot FP et al. | Fluidized bed adsorption for whole broth extraction. | 1990 Sep-Oct | Biotechnol. Prog. | pmid:1366874 |
| Blackham A and Griffiths RJ | The effect of FK506 and cyclosporin A on antigen-induced arthritis. | 1991 | Clin. Exp. Immunol. | pmid:1718639 |
| Carobbi A et al. | Effect of splenectomy in combination with FK 506 and 15-deoxyspergualin on cardiac xenograft survival. | 1991 | Transplant. Proc. | pmid:1703704 |
| Fukuda T et al. | Inhibition of antigen-induced late asthmatic response and bronchial hyperresponsiveness by cyclosporin and FK 506. | 1991 | Int. Arch. Allergy Appl. Immunol. | pmid:1718889 |
| Murase N et al. | FK 506 prevents spontaneous diabetes in the BB rat. | 1991 | Transplant. Proc. | pmid:1703705 |
| Meiser BM et al. | Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease. | 1991 | Lancet | pmid:1719321 |
| Watanabe K et al. | Donor bone marrow cell facilitates induction of tolerance to kidney allografts in dogs treated with fractionated lymphoid irradiation and FK 506. | 1991 | Transplant. Proc. | pmid:1703706 |
| Abu-Elmagd KM et al. | Strategy of FK 506 therapy in liver transplant patients: effect of graft function. | 1991 | Transplant. Proc. | pmid:1721272 |
| Ericzon BG et al. | Pharmacokinetics of FK 506 during maintenance therapy in liver transplant patients. | 1991 | Transplant. Proc. | pmid:1721273 |
| Jain AB et al. | Pharmacokinetics of cyclosporine and nephrotoxicity in orthotopic liver transplant patients rescued with FK 506. | 1991 | Transplant. Proc. | pmid:1721274 |
| McMichael J et al. | Evaluation of a novel "intelligent" dosing system for optimizing FK 506 therapy. | 1991 | Transplant. Proc. | pmid:1721275 |
| Ali Shah I et al. | Effects of FK 506 on human hepatic microsomal cytochrome P-450-dependent drug metabolism in vitro. | 1991 | Transplant. Proc. | pmid:1721276 |
| Connelly PR | Thermodynamics of interaction of FK 506-binding protein and its ligands. | 1991 | Transplant. Proc. | pmid:1721304 |
| Donnelly JG and Soldin SJ | Purification of a 50- to 58-kDa immunophilin from human spleen and a Jurkat T-cell line capable of binding cyclosporine A, FK 506, and rapamycin. | 1991 | Transplant. Proc. | pmid:1721305 |
| Rosborough SL et al. | Identification of FKBP-related proteins with antibodies of predetermined specificity and isolation by FK 506 affinity chromatography. | 1991 | Transplant. Proc. | pmid:1721306 |
| Zeevi A et al. | In vitro assessment of FK 506 immunosuppressive activity in transplant patients. | 1991 | Transplant. Proc. | pmid:1721307 |
| Katz HR et al. | Mast cell biochemical and functional heterogeneity. | 1991 | Transplant. Proc. | pmid:1721308 |
| de Paulis A et al. | Antiinflammatory effect of FK 506 on human basophils. | 1991 | Transplant. Proc. | pmid:1721309 |
| Lewis WD et al. | FK 506 rescue therapy in liver transplant recipients with drug-resistant rejection. | 1991 | Transplant. Proc. | pmid:1721336 |
| Woodle ES et al. | FK 506: reversal of humorally mediated rejection following ABO-incompatible liver transplantation. | 1991 | Transplant. Proc. | pmid:1721337 |
| Shaw BW et al. | FK 506 for rescue treatment of acute and chronic rejection in liver allograft recipients. | 1991 | Transplant. Proc. | pmid:1721338 |
| McDiarmid SV et al. | FK 506 rescue therapy in liver transplantation: outcome and complications. | 1991 | Transplant. Proc. | pmid:1721339 |
| Rucay P et al. | FK 506 rescue therapy for refractory acute rejection in five liver recipients. | 1991 | Transplant. Proc. | pmid:1721340 |
| Macleod AM and Thomson AW | FK 506: an immunosuppressant for the 1990s? | 1991 | Lancet | pmid:1702172 |
| Darras FS et al. | Transplantation of pediatric en bloc kidneys under FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1721368 |
| Shapiro R et al. | Kidney transplantation under FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1703352 |
| Todo S et al. | Clinical small bowel or small bowel plus liver transplantation under FK 506. | 1991 | Transplant. Proc. | pmid:1721369 |
| Tzakis AG et al. | Use of FK 506 in pediatric patients. | 1991 | Transplant. Proc. | pmid:1703353 |
| Fries D et al. | Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation. | 1991 | Transplant. Proc. | pmid:1721370 |
| Jain AB et al. | Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. | 1991 | Transplant. Proc. | pmid:1703354 |
| Wijnen RM et al. | Toxicity of FK 506 in the cynomolgus monkey: noncorrelation with FK 506 serum levels. | 1991 | Transplant. Proc. | pmid:1721371 |
| Venkataramanan R et al. | Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine. | 1991 | Transplant. Proc. | pmid:1703355 |
| Fung JJ et al. | Adverse effects associated with the use of FK 506. | 1991 | Transplant. Proc. | pmid:1721372 |
| Omar G et al. | FK 506 inhibition of cyclosporine metabolism by human liver microsomes. | 1991 | Transplant. Proc. | pmid:1703356 |
| DiMartini A et al. | Psychiatric morbidity in liver transplant patients. | 1991 | Transplant. Proc. | pmid:1721399 |
| Lopez OL et al. | Neuropathologic findings in liver transplantation: a comparative study of cyclosporine and FK 506. | 1991 | Transplant. Proc. | pmid:1721400 |
| Viebahn R et al. | Hypoxic and reoxygenation injury in human and rat hepatocytes--influence of FK 506 and cyclosporine. | 1991 | Transplant. Proc. | pmid:1721401 |
| Morrisett JD et al. | Effect of FK 506 and cyclosporine on plasma cholesterol levels in rabbits. | 1991 | Transplant. Proc. | pmid:1721402 |
| Jacobs TW et al. | The effect of FK 506, cyclosporine A, and cyclosporine G on serum 1,25-dihydroxyvitamin D levels. | 1991 | Transplant. Proc. | pmid:1721403 |
| Abu-Elmagd KM et al. | Acute hemolytic anemia in liver and bone marrow transplant patients under FK 506 therapy. | 1991 | Transplant. Proc. | pmid:1721404 |
| Gotoh M et al. | Tolerance induction by liver grafting and FK 506 treatment in nonhuman primates. | 1991 | Transplant. Proc. | pmid:1721431 |
| Valdivia LA et al. | Differential survival of hamster-to-rat liver and cardiac xenografts under FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1721432 |
| Wu GD et al. | FK 506 inhibits the development of transplant arteriosclerosis. | 1991 | Transplant. Proc. | pmid:1721433 |
| Kobayashi N et al. | Effect of FK 506 on abdominal organ cluster transplantation in pigs. | 1991 | Transplant. Proc. | pmid:1721434 |
| Wada H et al. | An attempt to induce tolerance to skin grafts in congenic mice with FK 506. | 1991 | Transplant. Proc. | pmid:1721435 |
| Hohlfeld R | [Current therapy of multiple sclerosis: value of cyclosporin A and FK 506]. | 1991 | Nervenarzt | pmid:1709725 |
| Kay JE et al. | Inhibition of T and B lymphocyte proliferation by rapamycin. | 1991 | Immunology | pmid:1709916 |
| Ringe D | Immunosuppression. Binding by design. | 1991 | Nature | pmid:1710317 |
| Tropschug M and Hofmann R | FK506 and protein kinase C. | 1991 | Nature | pmid:1710319 |
| Albers MW et al. | Relationship of FKBP to PKCI-2. | 1991 | Nature | pmid:1710782 |
| Stevens C et al. | The effects of immunosuppressive agents on in vitro production of human immunoglobulins. | 1991 | Transplantation | pmid:1710843 |
| McManus BM et al. | Impact of FK 506 on myocarditis in the enteroviral murine model. | 1991 | Transplant. Proc. | pmid:1721463 |
| Nossal GJ | Summary of the First International FK 506 Congress: perspectives and prospects. | 1991 | Transplant. Proc. | pmid:1721464 |
| Staruch MJ et al. | Differential effects of the immunosuppressive macrolides FK-506 and rapamycin on activation-induced T-cell apoptosis. | 1991 | Int. J. Immunopharmacol. | pmid:1721613 |
| Matsuura T et al. | [Experimental studies on the mode of action of cyclosporine and FK506 assessed by proliferation response of human cloned T lymphocytes]. | 1991 | Hinyokika Kiyo | pmid:1721767 |
| Morris PJ | Cyclosporine, FK-506 and other drugs in organ transplantation. | 1991 | Curr. Opin. Immunol. | pmid:1721824 |
| Lhoëst G et al. | Isolation and mass spectrometric identification of five metabolites of FK-506, a novel macrolide immunosuppressive agent, from human plasma. | 1991 | Pharm Acta Helv | pmid:1722046 |
| Simmons RL and Wang SC | New horizons in immunosuppression. | 1991 | Transplant. Proc. | pmid:1714645 |
| Calne RY | Immunosuppression for organ grafting. | 1991 | Transplant. Proc. | pmid:1714646 |
| Starzl TE et al. | Notes on FK 506. | 1991 | Transplant. Proc. | pmid:1714647 |
| Haba T et al. | Pathological and immunohistochemical examination in the rat treated with FK 506. | 1991 | Transplant. Proc. | pmid:1714649 |
| Lautenschlager I et al. | Efficiency of FK 506 and CyA to prevent acute cellular rejection of pig liver allografts. | 1991 | Transplant. Proc. | pmid:1714650 |
| Lane WS et al. | Complete amino acid sequence of the FK506 and rapamycin binding protein, FKBP, isolated from calf thymus. | 1991 | J. Protein Chem. | pmid:1718307 |
| Goto S et al. | Effect of FK 506 and cyclosporine on heart allograft survival in rats. | 1991 | Transplant. Proc. | pmid:1703700 |
| James DG | Which immunomodulator? | 1991 | Br J Clin Pract | pmid:1718384 |
| Flavin T et al. | Initial experience with FK 506 as an immunosuppressant for nonhuman primate recipients of cardiac allografts. | 1991 | Transplant. Proc. | pmid:1703701 |
| Jiang H et al. | Effect of FK 506 on heart allograft survival in highly sensitized recipient rats in comparison with cyclosporine. | 1991 | Transplant. Proc. | pmid:1703702 |